Surrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short Interest

Surrozen, Inc. (NASDAQ:SRZN) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 33,900 shares, a growth of 43.0% from the November 15th total of 23,700 shares. Based on an average daily trading volume, of 29,300 shares, the short-interest ratio is currently 1.2 days. Currently, 1.4% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SRZN. Stonepine Capital Management LLC raised its holdings in shares of Surrozen by 66.5% during the third quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock valued at $1,318,000 after acquiring an additional 43,916 shares during the period. Nantahala Capital Management LLC purchased a new position in Surrozen during the 2nd quarter worth approximately $2,050,000. CVI Holdings LLC acquired a new stake in Surrozen during the 2nd quarter valued at $711,000. Finally, Armistice Capital LLC purchased a new stake in shares of Surrozen in the second quarter valued at $2,080,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Surrozen Price Performance

Shares of NASDAQ:SRZN traded up $0.14 on Friday, reaching $9.85. 24,834 shares of the company traded hands, compared to its average volume of 17,884. The company’s 50 day moving average is $10.29 and its 200-day moving average is $9.75. Surrozen has a fifty-two week low of $6.00 and a fifty-two week high of $16.19.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($2.77) by $2.33. The company had revenue of $10.00 million for the quarter. As a group, equities analysts anticipate that Surrozen will post -7.16 EPS for the current fiscal year.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.